120 related articles for article (PubMed ID: 23138000)
1. The hazards of cross comparing the drug toxicity results from different trials in metastatic renal cancer: in response to a letter from Dr. Catalá-López.
Powles T; Sarwar N; Jones R; Wilson P; Boleti E; Protheroe A; Crabb S; Shamash J; Stockdale A; Lim L; Nathan P; Chowdury S
Eur J Cancer; 2013 Mar; 49(4):986-7. PubMed ID: 23138000
[No Abstract] [Full Text] [Related]
2. Safety of multikinase inhibitors in metastatic renal cell carcinoma and indirect treatment comparisons.
Catalá-López F
Eur J Cancer; 2013 Mar; 49(4):984-5. PubMed ID: 23140823
[No Abstract] [Full Text] [Related]
3. PISCES: a horoscope for first-line targeted therapy of metastatic renal cell carcinoma.
Sun M; Larcher A; Schiffmann J; Karakiewicz PI
J Clin Oncol; 2014 Nov; 32(33):3783. PubMed ID: 25267763
[No Abstract] [Full Text] [Related]
4. Benefits of pazopanib over sunitinib for renal cell carcinoma.
Granovetter M
Lancet Oncol; 2016 Mar; 17(3):e93. PubMed ID: 26853821
[No Abstract] [Full Text] [Related]
5. PISCES trial: the end does not always justify the means.
Barni S; Petrelli F
J Clin Oncol; 2014 Nov; 32(33):3782-3. PubMed ID: 25267749
[No Abstract] [Full Text] [Related]
6. How to interpret patient preferences in selecting the best drug: are the current measurements up to the job?
Garnick MB
J Clin Oncol; 2014 May; 32(14):1392-3. PubMed ID: 24687838
[No Abstract] [Full Text] [Related]
7. Reply to S. Barni et Al and M. Sun et Al.
Garnick MB
J Clin Oncol; 2014 Nov; 32(33):3785. PubMed ID: 25267752
[No Abstract] [Full Text] [Related]
8. Reply to S. Barni et Al and M. Sun et Al.
Escudier B; Porta C; Powles T; Eisen T; Sternberg CN; Mehmud F; Cella D
J Clin Oncol; 2014 Nov; 32(33):3783-4. PubMed ID: 25267750
[No Abstract] [Full Text] [Related]
9. An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer.
Powles T; Sarwar N; Jones R; Wilson P; Boleti E; Protheroe A; Crabb SJ; Shamash J; Stockdale A; Rashid S; Nathan P; Chowdury S
Eur J Cancer; 2012 Nov; 48(17):3171-6. PubMed ID: 22766517
[TBL] [Abstract][Full Text] [Related]
10. Kidney cancer: in crossover study, patients and physicians prefer pazopanib.
Phillips R
Nat Rev Urol; 2014 May; 11(5):246. PubMed ID: 24731995
[No Abstract] [Full Text] [Related]
11. Pazopanib outscores sunitinib on tolerability.
Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960
[TBL] [Abstract][Full Text] [Related]
12. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK
Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173
[TBL] [Abstract][Full Text] [Related]
13. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
Kim JH; Park I; Lee JL
Cancer Chemother Pharmacol; 2016 Aug; 78(2):325-32. PubMed ID: 27324136
[TBL] [Abstract][Full Text] [Related]
14. Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma.
Beaumont JL; Salsman JM; Diaz J; Deen KC; McCann L; Powles T; Hackshaw MD; Motzer RJ; Cella D
Cancer; 2016 Apr; 122(7):1108-15. PubMed ID: 27000445
[TBL] [Abstract][Full Text] [Related]
15. Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.
Vickers MM; Heng DY; Hemmelgarn B; Eigl BJ
Clin Genitourin Cancer; 2009 Oct; 7(3):E104-6. PubMed ID: 19815480
[TBL] [Abstract][Full Text] [Related]
16. Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors.
Iacovelli R; Verri E; Cossu Rocca M; Aurilio G; Cullurà D; de Cobelli O; Nolè F
Anticancer Drugs; 2017 Feb; 28(2):206-212. PubMed ID: 27754995
[TBL] [Abstract][Full Text] [Related]
17. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.
Escudier B; Porta C; Bono P; Powles T; Eisen T; Sternberg CN; Gschwend JE; De Giorgi U; Parikh O; Hawkins R; Sevin E; Négrier S; Khan S; Diaz J; Redhu S; Mehmud F; Cella D
J Clin Oncol; 2014 May; 32(14):1412-8. PubMed ID: 24687826
[TBL] [Abstract][Full Text] [Related]
18. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
[TBL] [Abstract][Full Text] [Related]
19. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
O'Donnell PH
BJU Int; 2011 Oct; 108(8):1284-5. PubMed ID: 21418138
[No Abstract] [Full Text] [Related]
[Next] [New Search]
